- Home
- Responsibility
- Commitment to transparency
- Patient group funding
- Pan European groups
Patient group funding
The European Federation of Allergy and Airways Diseases Patients Associations (EFA)
EFA is a European network of allergy, asthma and COPD patient organisations that was founded in 1991, prompted by the belief that an international organisation formed by European patients associations that share the same aims would be a more effective way to serve the needs and safeguard the rights of patients and their carers.
We have supported this organisation since 1997.
During 2010:
- We gave an unrestricted grant of €55,000 to help support their activities. We also gave an unrestricted grant of €15,000 to support phase two of EFA's research project that led to publication of a COPD patient and patient group resource.
- We also supported EFA in kind to the value of €7,561.90 to help them to produce a video on raising awareness of COPD.
Our support represents 19.06% of their overall income.
During 2009:
- We gave an unrestricted grant of €55,000 to help support their activities.
- We also gave EFA three honoraria of €500 and reimbursed travel and hotel expenses to support the attendance of the Executive Officer and at GSK’s European Health Advisory Board meetings.
Our support represents 39% of their overall income.
During 2008:
- We gave EFA an unrestricted grant of €55,000 to help them with their activities.
- We also gave an unrestricted grant of €15,000 to support phase one of EFA's research project that will lead to publication of a COPD patient and patient group resource.
- In addition we gave EFA two honoraria of €500 and reimbursed travel and hotel expenses to support the attendance of the Executive Officer at GSK’s European Health Advisory Board meetings.
Our support represents around 23.5% of their overall income.
During 2007:
- EFA received honorarium and expenses of €854.26 to enable the EFA Executive Officer participation in the GSK's Health Advisory Board meeting
- We gave EFA an unrestricted grant of €50,000 to help them with their activities.
Our funding represents around 14.41% of their income overall.
- We gave EFA an unrestricted grant of €50,000 to help them with their activities.
- We gave EFA an honorarium of £500 to support the attendance of the President at GSK's Global Burden of COPD advisory board.
- We gave EFA an honorarium of €500 and €290 travel costs for the Executive Officer's participation in GSK's European Patient Advisory Board.
During 2006:
Our funding represents around 17% of their income overall.
